LV-FAH Gene Therapy for Hereditary Tyrosinemia Type 1 (HT1)

LV-FAH Gene Therapy for Hereditary Tyrosinemia Type 1 (HT1)

LV-FAH

At a Glance

  • Hereditary tyrosinemia type 1 (HT1), a rare inborn error of metabolism of the liver, results from a single-gene mutation in fumarylacetoacetate hydrolase (FAH) that leads to cirrhosis, liver failure, hepatocellular carcinoma, and ultimately is fatal if untreated.
  • Affects approximately 1:100,000 live births with signs and symptoms appearing early in life. 
  • Currently managed through chronic administration of nitisinone, but liver transplantation is the only curative treatment available. 
  • Our investigational gene therapy (LV-FAH) is designed to transduce hepatocytes and deliver the FAH enzyme that is deficient in these cells.

About Hereditary Tyrosinemia Type 1

Meet Lottie

Hereditary tyrosinemia type 1 (HT1) is a rare inborn error of metabolism caused by a lack of the enzyme FAH that leads to the accumulation of tyrosine and its metabolites in the liver. HT1 affects approximately 1:100,000 live births and leads to cirrhosis, liver failure, hepatocellular carcinoma, and ultimately is fatal if untreated. Currently, HT1 is managed through chronic administration of the protective drug, nitisinone, which delays severe outcomes, but this management is associated with neurocognitive deficiencies. Liver transplantation is currently the only curative treatment available for HT1, which has its own life-long consequences.

About LV-FAH

Castle Creek is advancing preclinical development of LV-FAH, an in vivo investigational gene therapy for the treatment of HT1. LV-FAH is based on a lentiviral vector containing a functional copy of the human FAH gene which is administered directly to the patient through the portal vein. This therapy is designed to transduce hepatocytes and deliver the FAH enzyme that is deficient in these cells.

Castle Creek plans to submit an Investigational New Drug application for LV-FAH to the U.S. Food and Drug Administration for the treatment of HT1.


Explore Advocacy & Educational Resources


Photo: Courtesy of the Pratt family. Used with permission

Castle Creek Biosciences’ product candidates are investigational. None of our investigational gene therapies have received marketing approval by the U.S. Food and Drug Administration nor any other regulatory agency